BREVIBLOC IN NACL

Manufacturer:

BAXTER

Name:

BREVIBLOC IN NACL

HCPCS Code Descriptor:

Injection, esmolol hydrochloride, 10 mg

Category:

J Code

HCPCS:

J1805

NDC(s):

67457-0658-10, 67457-0657-25, 67457-0182-10, 63323-0652-10, 55150-0420-10, 55150-0421-10, 55150-0194-10, 25021-0314-10, 25021-0309-82, 25021-0308-84, 10019-0668-10, 10019-0670-10, 10019-0672-10, 10019-0666-10, 10019-0115-01, 10019-0120-01, 10019-0055-61, 10019-0075-87

Primary Type:

Cardiology

Generic Status:

Multi-Source

Route of Administration:

Intravenous

About:

BREVIBLOC IN NACL is a Cardiology drug manufactured by BAXTER and administered via the Intravenous route of administration. The J Code: J1805 is aligned to the drug BREVIBLOC IN NACL.

Brevibloc in NaCl is a selective beta-1 adrenergic antagonists and works by blocking stress hormones from performing actions on beta-1 receptors in the body. This medication mainly blocks the beta-1 receptors in the heart. Brevibloc in NaCl can be used to treat a variety of cardiovascular disorders. It can also be used to quickly control the heart rate of the patient during surgery. This medication is a generic medication that is manufactured by Auromedics Pharmaceuticals, Baxter, Sagent Pharmaceuticals, Fresenius Kabi, and Mylan Institutional.